Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

About 81,000 Baby Monitors Recalled Over Possible Fire Risk

WEDNESDAY, March 4, 2026 Parents who use baby monitors may want to take a closer look at the one they have at home. The U.S. Consumer Product Safety Commission

Your Furry Roommate May Be Affecting The Air You Breathe

WEDNESDAY, March 4, 2026 Dogs may bring more than companionship into a home They can also affect the air we breathe indoors, a new study shows. Researchers foun

Review of U.S. Measles Elimination Status Delayed Until November

WEDNESDAY, March 4, 2026 An expected review of the United States measles elimination status has been postponed by seven months. The meeting, originally schedule

Diltiazem Linked to Increased Risk for Bleeding Complications in A-Fib

For patients with atrial fibrillation (AF) receiving apixaban or rivaroxaban, use of diltiazem versus metoprolol is associated with an increased risk for seriou

New Model Performs Well for Detecting Alcohol-Associated Liver Disease

A novel predictive model demonstrates good performance for detecting metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated

Predictors of Prediabetes/T2DM Identified Among U.S. Adolescents

Male gender, younger age, and waist-to-height ratio are independent predictors of prediabetes type 2 diabetes mellitus (T2DM) among U.S. adolescents, according

Excess Prepregnancy Parental Adiposity Linked to Offspring MASLD

Prepregnancy parental overweight or obesity is associated with increased odds of offspring metabolic dysfunction-associated steatotic liver disease (MASLD) in a

Twenty Percent of Eligible Youth Prescribed GLP-1 Receptor Agonists

Twenty percent of potentially eligible youth are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with the odds of prescription higher with inc

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Genentech, a member of the Roche Group (SIX RO, ROG OTCQX RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its p

Theravance Biopharma Reports Phase 3 CYPRESS Study of Ampreloxetine Did Not Meet Primary Endpoint

Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the e

Popular Keywords